{
 "ticker": "BBC",
 "name": "Virtus Biotech Clinical Trials ETF",
 "issuer": "not established",
 "desk": "themes",
 "url": "https://etfiq.com/funds/BBC",
 "html": "https://etfiq.com/funds/BBC",
 "markdown": "https://etfiq.com/funds/BBC.md",
 "as_of": "2026-09-11",
 "verdict": "BBC holds 124 stocks, and 100% of its weight is outside the S&P 500.",
 "key_facts": [
  {
   "key": "already_in_the_s_p_500",
   "label": "Already in the S&P 500",
   "value": "0.0%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "BBC, already in the S&P 500: 0.0%, as of Sep 11, 2026."
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "100.0%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "BBC, active share vs the S&P 500: 100.0%, as of Sep 11, 2026."
  },
  {
   "key": "top_ten_holdings",
   "label": "Top ten holdings",
   "value": "16.2%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "BBC, top ten holdings: 16.2%, as of Sep 11, 2026."
  },
  {
   "key": "total_return_1_year",
   "label": "Total return, 1 year",
   "value": "+103.2%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "BBC, total return, 1 year: +103.2%, as of Sep 11, 2026."
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$37m",
   "source": "SEC filing, whole fund, as filed for Apr 30, 2026",
   "as_of": "2026-09-11",
   "sentence": "BBC, net assets: $37m (SEC filing, whole fund, as filed for Apr 30, 2026)."
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.65%",
   "source": "485BPOS XBRL, Feb 27, 2026",
   "as_of": "2026-09-11",
   "sentence": "BBC, expense ratio: 0.65% (485BPOS XBRL, Feb 27, 2026)."
  }
 ],
 "fields": [
  {
   "key": "theme",
   "label": "Theme",
   "value": "Biotech and genomics",
   "source": "ETFIQ, editorial"
  },
  {
   "key": "launched",
   "label": "Launched",
   "value": "Dec 17, 2014",
   "source": null
  },
  {
   "key": "already_in_the_s_p_500_by_weight",
   "label": "Already in the S&P 500, by weight",
   "value": "0.0%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "100.0%",
   "source": "ETFIQ"
  },
  {
   "key": "already_in_the_nasdaq_100_by_weight",
   "label": "Already in the Nasdaq-100, by weight",
   "value": "0.0%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_nasdaq_100",
   "label": "Active share vs the Nasdaq-100",
   "value": "100.0%",
   "source": "ETFIQ"
  },
  {
   "key": "top_ten_holdings_weight",
   "label": "Top ten holdings weight",
   "value": "16.2%",
   "source": null
  },
  {
   "key": "holdings",
   "label": "Holdings",
   "value": "124",
   "source": null
  },
  {
   "key": "holdings_as_of",
   "label": "Holdings as of",
   "value": "Apr 30, 2026",
   "source": "SEC N-PORT"
  },
  {
   "key": "top_holdings",
   "label": "Top holdings",
   "value": "ERASCA INC 2.2%, ENLIVEN THERAPEUTICS INC 1.8%, TANGO THERAPEUTICS INC 1.7%, ORUKA THERAPEUTICS INC 1.7%, SPYRE THERAPEUTICS INC 1.6%, ALUMIS INC 1.6%, DIANTHUS THERAPEUTICS INC 1.5%, KODIAK SCIENCES INC 1.4%, REVOLUTION MEDICINES INC 1.4%, CORVUS PHARMACEUTICALS INC 1.3%",
   "source": null
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$37m",
   "source": "SEC filing, whole fund, as filed for Apr 30, 2026"
  },
  {
   "key": "below_its_all_time_high",
   "label": "Below its all-time high",
   "value": "\u221217.8%",
   "source": "ETFIQ"
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.65%",
   "source": "485BPOS XBRL, Feb 27, 2026"
  },
  {
   "key": "fee_for_the_part_that_differs_from_the_s_p_500_active_expense_ratio",
   "label": "Fee for the part that differs from the S&P 500, active expense ratio",
   "value": "0.65%",
   "source": "ETFIQ"
  },
  {
   "key": "closest_funds_by_holdings_overlap",
   "label": "Closest funds by holdings overlap",
   "value": "CANC 20%, IBBQ 17%, FMED 14%, WDNA 13%, IBRN 11%",
   "source": null
  }
 ],
 "periods": [
  {
   "window": "3 months",
   "Total return": "+14.8%",
   "S&P 500": "+3.3%",
   "Gap to S&P 500": "+11.5 pts",
   "Gap to Nasdaq-100": "+15.6 pts"
  },
  {
   "window": "6 months",
   "Total return": "+21.5%",
   "S&P 500": "+16.0%",
   "Gap to S&P 500": "+5.5 pts",
   "Gap to Nasdaq-100": "+0.8 pts"
  },
  {
   "window": "1 year",
   "Total return": "+103.2%",
   "S&P 500": "+17.5%",
   "Gap to S&P 500": "+85.7 pts",
   "Gap to Nasdaq-100": "+80.2 pts"
  },
  {
   "window": "3 years",
   "Total return": "+137.7%",
   "S&P 500": "+77.9%",
   "Gap to S&P 500": "+59.8 pts",
   "Gap to Nasdaq-100": "+42.6 pts"
  },
  {
   "window": "Since launch",
   "Total return": "+95.7%",
   "S&P 500": "+361.5%",
   "Gap to S&P 500": "\u2212265.8 pts",
   "Gap to Nasdaq-100": "\u2212572.8 pts"
  }
 ],
 "questions": [
  {
   "q": "How much of BBC is in S&P 500 companies?",
   "a": "By its holdings filed for Apr 30, 2026, 0% of BBC by weight is stocks the S&P 500 already holds. Its active share against the index is 100%, so that share is the part doing something different."
  },
  {
   "q": "What does BBC hold?",
   "a": "124 positions as filed for Apr 30, 2026, with the top ten at 16% of the fund. The largest are ERASCA INC at 2.2%, ENLIVEN THERAPEUTICS INC at 1.8%, TANGO THERAPEUTICS INC at 1.7%."
  },
  {
   "q": "Has BBC beaten the S&P 500?",
   "a": "Over the year to Sep 11, 2026 BBC returned +103.2% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 85.7 points."
  },
  {
   "q": "What does BBC cost?",
   "a": "The prospectus expense ratio is 0.65% a year. Because 100% of the fund differs from the S&P 500, the fee on that differing part works out at 0.65%."
  }
 ],
 "generated": "2026-09-13",
 "license": "Free to use with attribution. ETFIQ (etfiq.com)."
}